Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.24.3
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Product Information [Line Items]        
Total net revenue $ 2,350,386 $ 298,484 $ 7,154,429 $ 319,143
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Total net revenue [1]     6,259,806 248,654
Histology Service Fees [Member]        
Product Information [Line Items]        
Total net revenue     811,914 31,854
Health Care, Other [Member]        
Product Information [Line Items]        
Total net revenue     50,136 2,393
Department of Defense Observational Studies [Member]        
Product Information [Line Items]        
Total net revenue     8,654 14,250
Other Revenues [Member]        
Product Information [Line Items]        
Total net revenue [2]     $ 23,919 $ 21,992
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $332,000 and $24,000 for the nine months ended September 30, 2024 and 2023.
[2] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.